Drug Profile
Research programme: cardiovascular disease therapy - Lipid Sciences
Alternative Names: Cardiovascular disease therapy research programme - Lipid SciencesLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Lipid Sciences
- Class Lipoproteins
- Mechanism of Action Apolipoprotein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cardiovascular disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cardiovascular-disorders in USA
- 02 Jun 2004 Preclinical trials in Cardiovascular disorders in USA (unspecified route)